Axsome Therapeutics, which is developing novel therapies for pain and CNS disorders utilizing the 505(b)(2) pathway, announced terms for its IPO on Monday.
The New York, NY-based company plans to raise $51 million by offering 4.3 million shares at a price range of $11 to $13. At the midpoint of the proposed range, Axsome Therapeutics would command a fully diluted market value of $224 million.
Axsome Therapeutics, which was founded in 2012, plans to list on the Nasdaq under the symbol AXSM. Ladenburg Thalmann & Co. is the sole bookrunner on the deal. It is expected to price during the week of November 16, 2015.
